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Microsomal triglyceride transfer protein (MTP) plays an essential role
in lipid metabolism, especially in the biogenesis of very low-density
lipoproteins and chylomicrons via the transfer of neutral lipids and
the assembly of apoB-containing lipoproteins. Our understanding of
the molecular mechanisms of MTP has been hindered by a lack of
structural information of this heterodimeric complex comprising an
MTPα subunit and a protein disulfide isomerase (PDI) β-subunit. The
structure of MTP presented here gives important insights into the
potential mechanisms of action of this essential lipid transfer mole-
cule, structure-based rationale for previously reported disease-
causing mutations, and a means for rational drug design against
cardiovascular disease and obesity. In contrast to the previously
reported structure of lipovitellin, which has a funnel-like lipid-binding
cavity, the lipid-binding site is encompassed in a β-sandwich formed
by 2 β-sheets from the C-terminal domain of MTPα. The lipid-binding
cavity of MTPα is large enough to accommodate a single lipid. PDI
independently has a major role in oxidative protein folding in the
endoplasmic reticulum. Comparison of the mechanism of MTPα bind-
ing by PDI with previously published structures gives insights into
large protein substrate binding by PDI and suggests that the previous
structures of human PDI represent the “substrate-bound” and “free”
states rather than differences arising from redox state.
X-ray crystallography | abetolipoproteinemia | hypercholesterolemia |
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The transport of the bulk of dietary and endogenous lipids isachieved by the assembly of chylomicrons and very low-density
lipoproteins (VLDL; also called apolipoprotein B [apoB]-containing
lipoproteins), which are produced in the intestine and liver, re-
spectively (1–3). These large spherical particles contain apoB in
addition to triglycerides (TGs), cholesteryl esters (CEs), phos-
pholipids, and vitamins A and E. Current evidence suggests that
the assembly of apoB-containing lipoproteins is a 2-step process
occurring in the lumen of the endoplasmic reticulum (ER) (4). In
the first step, a small amount of lipid is transferred to nascent
apoB during translocation into the ER lumen, forming a pri-
mordial apoB particle. During the second step, lipid is added to
the primordial apoB particle posttranslationally. The first step
requires the ER-resident microsomal triglyceride transfer pro-
tein (MTP), which shuttles TG, CE, and phospholipids from the
ER membrane to the primordial apoB particle (5). Without
MTP function, underlipidated apoB is subjected to proteasomal
degradation (6, 7). Defective or missing MTP function leads to
abetalipoproteinemia (ABL; Online Mendelian Inheritance in
Man database 200100), a rare autosomal recessive disorder (8–
10). The disorder is characterized by a defect in assembly and
secretion of hepatic and intestinal apoB-containing lipoproteins,
VLDL, and chylomicrons, leading to fat malabsorption, sub-
sequent steatorrhea, and fat-filled enterocytes and hepatocytes.
Multiple point mutations within the MTTP gene resulting in
ABL have been reported and characterized (11–18). MTP is the
target for drugs to treat familial hypercholesterolemia in humans
(19–21) and obesity in dogs (22).
MTP is a heterodimer consisting of a unique large MTP
α-subunit (∼97 kDa) and a multifunctional protein disulfide
isomerase (PDI) β-subunit (∼55 kDa) (23, 24). PDI is a ubiqui-
tously expressed member of the thioredoxin superfamily, which
catalyzes oxidation and isomerization of disulfide bonds during
nascent protein folding (25). PDI comprises 4 thioredoxin-fold
domains, of which 2 are catalytic, a and a′, and contain a char-
acteristic CXXC catalytic motif (WCGHCK). The catalytic do-
mains are separated by b and b′ domains, with the b′ domain
providing the primary peptide binding site (26). The role of PDI in
MTP function is uncertain beyond a role in maintaining MTPα in
a soluble form (27) or ensuring that it remains in the ER through
a C-terminal KDEL ER retrieval signal (5, 28).
MTP is a member of the large lipid transfer protein (LLTP)
superfamily, which also includes apoB, apolipophorin I/II, and
lipovitellin (29). Apolipophorin I/II, the major carrier of lipids in
insects, and lipovitellin, which transports lipids to the developing
oocyte in oviparous vertebrates and invertebrates, together with
apoB function as vehicles for extracellular lipid transport. In
contrast to other family members, MTP is not directly involved in
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lipid transport to distant tissues and is not secreted. Evidence
suggests that MTP may be the oldest member of the LLTP su-
perfamily, which has given rise to paralogous family members,
including apoB (30).
Members of the LLTP superfamily share significant sequence
homology and a conserved N-terminal module consisting of a
β-barrel and an α-helical domain (30, 31). The C-terminal lipid-
binding domain has diverged among LLTP family members,
reflecting their abilities to bind different types and quantities of
lipid. Based on sequence and domain architecture similarity,
MTP, the smallest member of the family, has been predicted to
consist of 3 domains: an N-terminal β-barrel domain, a central
α-helical domain, and a C-terminal 2 β-sheet domain. A large
body of published evidence has suggested separate functions for
the domains. MTP acts as a chaperone and stabilizes the nascent
apoB molecule via interactions with the β-barrel and central
helical domains (32, 33). The central α-helical domain is repor-
ted to also act as the binding site for PDI (32). Lipid-binding and
transfer activity occurs in the C-terminal domain, with a strong
preference toward neutral 3 chain-containing lipids (34).
Among all LLTP members, only the crystal structure of lam-
prey lipovitellin has been reported to date (35–37). This struc-
ture provided an essential structural basis for understanding lipid
binding and transfer by this class of proteins. However, the wide
divergence in the lipid-binding domains in the superfamily hin-
ders understanding of the molecular mechanisms of action of
other families. Here, we describe the crystal structure of the
heterodimer of human MTP at 2.5-Å resolution. The structure
reveals the lipid-binding site in MTP, gives a rationale for
disease-causing mutations, and gives insights on the molecular
mechanisms of PDI interaction with large protein substrates.
Given the ability of MTP to modulate the concentration of apoB-
containing lipoproteins in blood plasma, the crystal structure also
provides the means for the rational drug design against obesity and
cardiovascular disease.
Results and Discussion
Overall Structure of MTP–PDI Protein Complex. To provide a struc-
tural basis to facilitate the understanding of the mechanisms of
action of lipid transfer by MTP, we determined the crystal struc-
ture of the full-length heterodimeric protein complex to 2.5 Å
(structure quality is in SI Appendix). Overall, the MTP complex
adopts a large extended cradle-like structure measuring ∼130 Å in
the longest direction and ∼80 Å in the shortest, and it contains
∼2,100 Å2 of buried area at the interface between the 2 subunits.
As reported previously and as evident from the crystal structure,
MTPα comprises 3 distinctive domains (Fig. 1): 1) an N-terminal
half β-barrel (amino acids 21 to 297), suggested to be involved in
interactions with apoB (32); 2) an α-helical domain (amino acids
298 to 603), previously proposed to be implicated in interaction
with PDI and apoB (32, 33); and 3) a C-terminal domain (amino
acids 604 to 884), which encompasses the lipid-binding site sand-
wiched between 2 β-sheets named the A- and C-sheets.
Fig. 1. Structure of MTP. (A) Domain architecture of PDI (Left) and MTP (Right). The Cys-Gly-His-Cys active site motifs of PDI are indicated. (B) Ribbon
representation of the MTPα–PDI complex structure. The 3 views are related by a 90° rotation around a vertical axis. The complex is colored according to A. The
missing region (MTPα amino acids 717 to 721) is shown by broken lines. Bound PEG is shown in stick representation in cyan. (C–E) Ribbon representation of the
β-barrel domain (C), α-helical domain (D), and lipid-binding domain (E). Cysteine residues are shown in ball and stick representation and colored in red. The
N-terminal β-barrel domain has a gap between strands β5 and β6, allowing a few residues (Asn147 and Arg150) of the central α-helix to be exposed and form
hydrogen bonds with the coil connecting the β-barrel and α-helical domains. In the α-helical domain, 3 layers of side chains are formed by the 2-layer ar-
rangement of the α-helices. There is a large buried surface between 2 layers of helices formed by hydrophobic residues and an additional surface formed
between the helical domain and the β-sheets of the C-terminal domain. The outer surface contains more polar and ionizable side chains.
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In a structure similar to that of lipovitellin (SI Appendix, Fig.
S1A), the N-terminal β-barrel consists of 3 short α-helices and 13
β-strands, which surround the fourth longer α-helix (Fig. 1C).
The β-barrel is not a continuous structure, having one side being
formed by shorter β-strands. The unusual shape of the β-barrel
domain results in the formation of a pit that, similar to lipovitellin,
accommodates the β-strand segments and loops of the A-sheet of
the C-terminal domain (SI Appendix, Fig. S1 A and C). The longer
side of the β-barrel forms a slightly twisted β-sandwich with 3 strands
of the A-sheet and is predominantly stabilized by hydrophobic in-
teractions. Previous publications refer to this region as a flexible
“ball-and-socket” junction, which might accommodate lipid (36, 37).
In contrast to lipovitellin, the N-terminal β-barrel domain contains
only 1 disulfide bond between Cys174 and Cys194. This is conserved
in lipovitellin (Cys156 to Cys182) and apoB (Cys186 to Cys212), and
it braces together a coiled region between strands β7 and β8 with
strand β7 (Fig. 1C). The second pair of cysteines forming a disulfide
bond, Cys289 and Cys301, is located in the long coiled segment
connecting the N-terminal β-barrel and the middle α-helical domain
(Fig. 1D and SI Appendix, Fig. S1 B and C). This disulfide is not
present in lipovitellin or apoB.
The α-helical domain of MTPα is similar to that of lipovitellin
(SI Appendix, Fig. S1B) and forms a superhelical right-handed
coiled-coil with a 2-helix repeating unit (Fig. 1D). The domain
encompasses 2 layers of 17 helices and 1 310-helix forming a
clamp, which holds together one side of the C-sheet and A-sheet
of the C-terminal lipid-binding cavity and encloses it from the
solvent. From the other side, the C-terminal domain is braced by
extensive interactions between the a′ domain of PDI and MTPα.
A region between helices α8 and α9 is stabilized by a disulfide
bond between Cys440 and Cys445 (Fig. 1D) in a position equiva-
lent to that found in lipovitellin (Cys443 to Cys449). This disulfide
is not conserved in apoB and is not conserved in the MTP family
(see below). One unpaired, nonconserved Cys397 is buried within
the hydrophobic core of the domain.
The C-terminal domain of MTP is formed by 2 β-sheets, which
according to convention, are named the A- and C-sheets. The
A- and C-sheets form a slightly twisted sandwich (Fig. 1E), which
encompasses the lipid-binding site between them. This is in stark
contrast with the funnel-like structure found in lipovitellin (SI Ap-
pendix, Fig. S1C). The narrow lipid-binding cavity of MTP reflects
its ability to bind only a limited amount of neutral lipid at a time—
as has been previously suggested by biochemical evidence (38). The
C-sheet is formed from 6 antiparallel β-strands, which line the
C-terminal part of the α-helical domain. The A-sheet is also formed
from 6 antiparallel β-strands, which are twice as long as than those
of the C-sheet. One-half of the A-sheet forms a lipid-binding site
with C-sheet (see below), and the other half interacts with the
N-terminal β-barrel domain. There are few interactions between
the A- and C-sheets, and these mostly occur on the edges of the
β-sandwich, blocking access to the lipid-binding site from solvent.
There is an 11-amino acid α-helix at the end of the C-terminal
domain. It is positioned at ∼90° relative to strand β5 of the A-sheet
and is stabilized in this conformation by 2 hydrogen bonds be-
tween the side chain of Asn874 and the backbone of Met828 and
by a disulfide bond between Cys827 and Cys878 (Fig. 1E). This
disulfide is important for the tertiary structure of MTP and its
function—mutation of Cys878 to Ser results in lower expression
and loss of lipid-transferring activity (11). An unpaired, non-
conserved, Cys866 located in strand β6 faces the lipid-binding site.
PDI in the complex adopts the horseshoe shape seen pre-
viously (39, 40), and all 4 domains (a, b, b′, and a′) are clearly
defined in our heterodimer structure (Fig. 1B). MTPα interacts
with PDI via its α-helical and C-terminal domains.
Interactions with PDI. MTPα interaction with PDI is obligatory,
and disruption of the heterodimer leads to the loss of the lipid
transfer activities and aggregation of the large MTPα subunit
(27). Experimental evidence and the crystal structure presented
here both indicate that the association of PDI and MTP is pre-
dominantly hydrophobic. PDI interacts with MTPα via 3 of its
4 domains: a, a′, and b′ (Figs. 1B and 2A). Comparison of in-
teractions formed by the a, a′, and b′ domains of PDI reveals
that the b′ domain provides a primary binding site for MTP,
consistent with previous biochemical evidence that it provides
the primary binding site for other protein substrates (26).
MTPα interacts with the b′ domain of PDI via the C-terminal
half of helix α17 of the helical domain and the loop (amino acids
594 to 610) on the border between the α-helical domain and
C-sheet. This loop protrudes from the surface of MTP and in-
teracts with a hydrophobic pocket in the b′ domain (Fig. 2 B and
C). Tyr605 of MTPα plays a major role in this interaction and
creates multiple contacts with residues lining the binding pocket
of PDI. The interaction of Tyr605 of MTPα with PDI is supported
by several hydrogen bonds formed by neighboring residues and by
the side chain of Met600 binding in a spatially adjacent hydro-
phobic pocket. Asn604 seems to play a critical role in fixing the
conformation of this loop as its side chain forms hydrogen bonds
with the backbone of Met600, Asp606, and Arg607. Asn604 and
Tyr605 are conserved in MTPα.
The a and a′ catalytic domains of PDI use equivalent surfaces to
interact with MTPα, with the catalytic CGHC motifs buried at the
interface. The active site cysteines in both catalytic domains of PDI
are in the reduced state, and the surface-exposed N-terminal cat-
alytic cysteines are located within 4 Å of MTPα (Fig. 2 D and E).
The a domain interacts with side chains of helices α13 and α15 of
the α-helical domain (Fig. 2D). The a′ domain makes contacts with
residues in the lipid-binding domain, including strands β5 and β6 of
the A-sheet, β1 of the C-sheet, and the C-terminal α-helix (Fig. 2E).
Lipid-Binding Site of MTP. The primary function of MTP is the
transfer of lipids for the assembly and secretion of VLDLs by the
liver and chylomicrons by the intestine (5). The lipid-binding
pocket of MTP has been suggested to be hydrophobic in nature
based on the distinctive preference of MTP toward neutral lipids
compared with charged lipids (34). However, it is capable of bind-
ing and transferring a wide variety of lipid molecules, suggesting
either promiscuity of binding or the presence of multiple lipid-
binding sites.
In the MTP crystal structure, there is a molecule of poly-
ethylene glycol (PEG) bound between β-sheets A and C, and this
probably occupies the lipid-binding site—with the PEG molecule
being considered as a lipid mimic (Fig. 3 and SI Appendix, Fig.
S2). PEG is bound in both MTPα chains of the asymmetric unit
in different conformations, reflecting the flexibility of lipid
binding. When compared with lipovitellin (SI Appendix, Fig.
S1C), the lipid-binding pocket of MTP is not a funnel-like
structure, but instead, it is a confined space. The calculated
volume of the cavity is ∼2,100 Å3 (41), comparable with the
volume of a single triacylglyceride molecule (∼1,620 Å3 for tri-
olein). This is in agreement with previous biochemical evidence
that the lipid-binding site can accommodate only a small number
of lipid molecules with a maximal number of observed bound
triolein of less than 1 per MTP (38). One of the bound PEGs
(cyan in Fig. 3) interacts along the entire length of the lipid-
binding pocket and runs parallel to the A-sheet between strands
β3 and β4 and between strands β2 and β4 and across β3 of the
C-sheet (Fig. 3 B and C). The second bound PEGmolecule (green
in Fig. 3) interacts closer to the “pivot” formed by the C-sheet and
the N-terminal domain; starting from the middle between strands
β3 and β4 of the A-sheet, it takes a turn across strand β4 and
extends a small tail between strands β4 and β5.
Electrostatic surface analysis of the inner interfaces of A- and
C-sheets indicates the presence of a predominantly neutral sur-
face (SI Appendix, Fig. S2A), which would favor binding of
neutral lipid moieties, such as TGs. No distinctive charged
patches are visible on the inner interface of the lipid-binding
pocket, which could bind charged head groups of phospholipids
or phosphatidylcholines. Previous studies showing that MTP is
capable of binding and transferring a wide class of lipids, in-
cluding phospholipids, from the ER membrane suggested the
presence of a second “slow” binding site in MTP (34, 38). It is
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Fig. 2. Interactions between PDI and MTPα. (A) Interactions between MTPα (Left) and PDI (Right) are shown in surface representation in yellow (a domain of
PDI and α13 and α15 helices of the α-helical domain of MTPα), pink (b′ domain of PDI binding mainly to the helix α17 and the loop connecting the α-helical
domain to the C-terminal domain of MTPα), and green (a′ domain of PDI interacting with β1-strand of C-sheet, β5- and β6-strands of A-sheet of MTPα, and 11-
amino acid C-terminal α-helix). The C-terminal α-helix is indicated with C. To expose the interacting surfaces, PDI was pulled away fromMTPα and rotated 180°
around a vertical axis and 90° around the z axis. (B) Close-up view at the interaction of MTPα with the b′ domain of PDI. (C) The view is related to B by ∼180°
rotation around the y axis and depicts a hydrophobic surface representation of the b′ domain of PDI with the hydrophobic residues colored in tan. The
interacting loop of MTPαmakes 2 turns and inserts the side chains of Met600 and Tyr605 into hydrophobic pockets of the b′ domain. (D and E) Close-up views
at interactions of MTPα with the a (D) and a′ (E) domains of PDI. Interacting residues are shown in stick representation and colored according to Fig. 1.
Cysteine residues of both protein molecules are shown in ball and stick representation. Cysteines of the active site motifs (Cys53-Gly54-His55-Cys56 and Cys397-
Gly398-His399-Cys400) of PDI are in the reduced state. Cys827 and Cys878 of MTPα form a disulfide bond. Hydrogen bonds are shown in dashed black lines.
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not possible to confirm such an additional site on the current
structure, but it could be speculated that a conformational
change in MTP may result in a second lipid-binding site at the
interface sandwiched between the A-sheet and the N-terminal
β-barrel domain. This region contains some positively charged
side chains, which may interact with charged phosphoryl groups.
To confirm the correct identification of the lipid-binding site,
7 mutations were made in the cavity (L633F, S662L, V664F,
V664H, V664Y, V778L, and F813H). The V664H mutant caused
strong growth defects even uninduced, and the V664Y mutant was
produced in low yields; therefore, they were not studied further.
Mutations L633F and F813H showed significantly reduced lipid
transfer activity, while S662L, V664F, and V778L showed higher
activity than the wild-type enzyme (SI Appendix, Fig. S3B). The
mutations with the greatest effect on activity, V664F and F813H,
were purified on a larger scale to confirm that the change in
activity did not result from altered folding and/or instability (SI
Appendix, Fig. S3 C, D, and F).
Mutations Causing ABL. Understanding of the role of MTP in
apoB transfer and assembly in part emerged from the discovery
of mutations in MTPα that cause ABL (42–44). To date, at least
18 natural missense variants of theMTTP gene have been reported,
with 10 of these being reported to cause ABL. In addition, a
number of frameshift, nonsense, and splice-site mutations leading
to a complete loss of MTP have been reported (11, 12, 43–49). No
mutations in the gene for PDI have been reported to cause ABL.
This is consistent with the interaction site between them being the
same as that used by PDI for substrate proteins, and hence, any
mutations in PDI, which could lead to ABL, would instead be le-
thal. Several missense mutations in MTTP known to cause ABL
have been extensively studied in vitro in an attempt to gain insights
into the role of each of 3 MTPα domains in PDI binding and lipid
transfer activity (15–18, 50, 51). Based on the crystal structure,
more insights can be made into these mutations.
The reported mutations can be broadly grouped into 2 categories:
those that abolish binding to PDI and transfer of lipids and those
that retain the ability to bind to PDI but abolish lipid transfer (Fig.
4). The former group includes D169V (16), D361Y (17), R540C
(15), R540H (12), and a 30-amino acid truncation from the C ter-
minus (18). From the crystal structure, all 4 point mutations might be
predicted to either result in misfolding or significantly destabilize the
native state by disrupting salt bridges (D169V, D361Y) or hydrogen
bonding (D169V, D361Y, R540C, R540H). In addition, Arg540 is
located in close proximity to the a domain of PDI; hence, its mu-
tation may have a direct negative impact on PDI association. The
30-amino acid truncation of MTP from the C terminus will nearly
completely eliminate the interaction site with the a′ domain of PDI.
Mutations that have been reported to retain the ability to bind
PDI but abolish lipid transfer include L435H (14), Y528H (15),
and S590I (51) in the helical domain and N649S (15), G746E
(51), and N780Y (51) in the lipid-binding domain. Of these
6 amino acids, only Asn780 faces the lipid-binding site directly.
Hence, the N780Y mutation may directly affect lipid binding.
The other 5 mutations probably affect lipid transfer activity in-
directly by inducing conformational change and/or destabilizing
the structure through the loss of structure-stabilizing hydrogen
bonds (Y528H, S590I, N649S), the disruption of a hydrophobic
interface (L435H), or the exposure of a hydrophobic side chain
(S590I). Of the 6 amino acids, only Gly746 is conserved. Gly746
Fig. 3. Lipid-binding site of MTPα. (A) The lipid-binding site is formed by a
sandwich between the A- and C-sheets (surface representation). (B and C)
Close-up view of the lipid-binding site of the C-sheet (B) and A-sheet (C) with
PEG molecules bound (depicted in cyan color from chain H and green color
from chain G). The lipid-binding site is formed mostly from hydrophobic
residue side chains. The side chains of Phe767, Thr776, Val778, Asn780,
Phe813, Ser815, Val817, and Phe819 of the A-sheet and Leu633, Ile642,
Leu643, Ser646, Leu648, Ile650, Ser662, Val664, Ile666, and Leu696 of the
C-sheet are within 4.5 Å of the PEG molecule from chain H. PEG from chain G
is placed within 4.5-Å distance from side chains of Val778, Asn780, Ala809,
Leu811, and Phe813 of the A-sheet and Ile621, Leu633, Ser646, Leu648,
Ile650, Gly661, Ser662, Val664, Ile666, and Leu696 of the C-sheet.
Fig. 4. Mapping of ABL-causing mutations to the MTP crystal structure.
Residues, the mutations of which are reported to abolish lipid transfer but
retain the ability to bind PDI, are shown in orange balls. Residues, the mu-
tations of which are reported to abolish the binding of PDI and transfer of
lipids, are indicated by blue balls. The C-terminal 30-amino acids truncation
of MTP is also shown in blue.
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forms part of the tight turn between β-strands β1 and β2 of
A-sheet and has φ/ψ values that are not permitted to other amino
acids. The G764E mutation is likely to severely disrupt the in-
teractions between the A-sheet and the β-barrel domain.
To confirm this structural analysis, 9 missense mutations inMTTP
that cause ABL were made. Seven of these (D169V, L435H, Y528H,
R540C, R540H, G764E, and N780Y) could not be produced in our
system or were produced in yields too low to analyze (<5% of wild-
type protein). Hence, most of the mutations seem to cause folding
and/or stability defects consistent with the prior literature and our
structure-based analysis. Two mutants (S590I and N649S) could be
made in higher yields but were still ∼3 to 4 times lower than that of
the wild-type protein. Both show decreased lipid transfer activity but
CD spectra and thermal denaturation curves equivalent to the wild-
type protein (SI Appendix, Fig. S4). Hence, these mutations seem to
affect both folding efficiency and lipid transfer activity.
Bioinformatics Analysis of MTP from Different Species. MTP is sug-
gested to be the oldest member of the LLTP superfamily (30)
and as such, can be found in a wide range of eukaryotic species.
Studies on the evolution of MTP have suggested the coemergence
of triacylglycerol transfer activity of MTP and apoB (52) such
that mammals, birds, and fish (and other vertebrates) have TG
transfer activity and possess apoB, while insects lack both. How-
ever, Drosophila MTP can support secretion of human apoB (53),
suggesting overlapping conservation of function.
Since residues involved in function are usually conserved, we
undertook structure-based conservation analysis to determine criti-
cal residues for MTP function. A dataset of 300 MTP sequences
from different organisms was split into subsets containing 216 ver-
tebrate sequences, 156 mammalian + bird sequences, and 94 mam-
malian sequences. Generally, conservation in the mammalian subset
was too high to yield useful information, but it supported the con-
clusions drawn from the other sets. Conservation of amino acids in
each of the sets was then mapped back onto the primary (SI Ap-
pendix, Fig. S5) or tertiary structure (Fig. 5A) of human MTP. Since
the larger dataset is more likely to contain DNA sequence errors,
the conservation threshold for this was chosen to be 98%. In each
dataset examined, conservation in the lipid-binding domain was
higher than in either of the other domains (Table 1).
Within the β-barrel, conservation was limited (conservation
3.6%; 8.9% within the vertebrate subset). Apart from Trp69 and
Gly130, which were conserved in all datasets, conservation was
located predominantly in the long central α-helix and the fol-
lowing 2 β-strands (β6 and β7) (SI Appendix, Figs. S5 and S6).
None of the conserved residues—even within the more homol-
ogous mammalian + bird data subset (22.5% conservation)—
were on the surface of the protein (Fig. 5B), raising questions
regarding the proposed interaction between this domain and
apoB. Even within the highly conserved mammalian subset
(34.6% conservation), the majority of conserved residues in the
β-barrel domain were buried, and the only surface-exposed patch
of conserved amino acids was centered on the N-terminal region
before β1, the farthest point in MTP from the lipid-binding site.
Within the α-helical region, conservation was higher than that
for the β-barrel within all datasets (Table 1), but still, the solvent
exposure of the conserved residues was minimal. Within the ver-
tebrate subset, no linear stretches of amino acids showed high
conservation (SI Appendix, Fig. S6). While the C terminus of
α6 ending in Cys397 showed high conservation in the mammalian +
bird subset (Fig. 5A and SI Appendix, Fig. S6), all of these residues
are buried in the core of the protein. In all sets (SI Appendix, Fig.
S5) residues interacting with the tip of the C-sheet were conserved,
including Asn479, Glu570, and Asp361, which all form structure-
stabilizing hydrogen bonds. Two of the residues within 5 Å of the a
domain of PDI are conserved in the vertebrate subset, Gln530 and
Arg540, with Arg540 conserved in every MTP sequence examined.
It is unclear what the function of these 2 residues is, but mutations
in Arg540 are reported to cause ABL (12, 15). The closest residues
in PDI to the side chain of either are Pro51 or Trp52, but the
closest distance is nearly 5 Å, while the side chains of Gln530 and
Arg540 are within 3.4 Å of each other.
The conservation within the lipid-binding domain was the
highest (Table 1 and SI Appendix, Figs. S5 and S6); despite virtually
no conservation in the region of the A-sheet in contact with
β-barrel, 2 of 68 amino acids in the vertebrate subset are conserved.
Fig. 5. Structure-based analysis. Structure-based conservation analysis of MTPα from the full (300 sequences; dark red), vertebrate (216 sequences; dark red
and orange), and mammalian + bird (156 sequences; dark red, orange, and yellow) data subsets. Residues N147, Q358, T368, P552, Y574, L743, G763, L769,
and L870 are conserved in 300 (98%) and mammalian + bird sets but not in the vertebrate sets, and the residues A374, A690, G746, and G755 are conserved
only within the 300 (98%) subset. (A) Conserved residues from 3 subsets are mapped on the MTPα structure. Conservation is limited within the β-barrel and
α-helical domains and mostly clustered in the lipid-binding segment of the C-terminal domain. PDI is shown in pink. Conserved residues mentioned in the text
are indicated. (B) MTPα structure is shown in surface representation in 3 different views identical to those in Fig. 1B, indicating that there are no apparent
conserved surface-exposed patches except for the middle view face of the lipid-binding site. (C) Ribbon representation of the lipid-binding domain with
conserved residues from all 3 subsets shown. The conservation is poor in the sites of interaction of A-sheet with the β-barrel and within the lipid-binding site.
(D) Close-up view of the middle orientation from B showing regions of conserved residues that might be involved in interactions with apoB. The majority of
conserved residues are surface exposed and located in the loops connecting β-strands and 2 sheets (amino acids 702 to 714 and 768 to 770).
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Excluding this part, vertebrate conservation in the lipid-binding
region is 23.0%, more than 2.5-fold higher than in either of the
other domains, suggesting functional importance. The expected
high conservation in the lipid-binding site, however, is not visible
(Fig. 5C). Only 4 of 23 amino acids within 4.5 Å of the bound PEG
are conserved among vertebrates, while in the mammalian + bird
dataset, only 9 of 23 are conserved. Instead of conserved amino acids,
the lipid-binding site contains similar—predominantly hydrophobic—
amino acids. This similarity, rather than conservation, is consis-
tent with MTPs capability to bind and transfer a wide variety of
lipid molecules. This is also consistent with the inability to pro-
duce mutants that introduce less hydrophobic residues in these
sites V664H, V664Y, and N780Y, while making hydrophobic
substitutions (S662L, V664F, V778L) did not inhibit MTP lipid
transfer activity.
The lipid-binding domain forms interactions with the b′ and a′
domains of PDI. Of the 26 amino acids of this domain within 4.5 Å
of PDI, 7 are conserved among vertebrates, and 3 of these are also
conserved in the 300 (98%) set (Fig. 5D). These 3 are Asn604 and
Tyr605, which make intimate contact with the b′ domain of PDI, as
well as Cys878, which forms a disulfide bond with Cys827 near the a′
domain. The highest conservation in the lipid-binding domain is
neither at the lipid-binding site nor near the PDI interaction site
(Fig. 5D and SI Appendix, Fig. S6). Instead, 67% of the amino acids
in the region Arg702 to Lys716 are conserved in the vertebrate
subset. Leu713 and Met714 along with Ser768 to Trp770 form a
conserved surface-exposed patch, which is extended in to a cleft
between the lipid-binding domain and the helical domain by
Phe706 and Phe707. These regions act as loops linking the β-strands
that form the lipid-binding cavity. As these are the only conserved
surface-exposed residues, it is tempting to speculate that this con-
served surface-exposed patch may form an interaction site for an-
other protein (e.g., the binding site for apoB) and that binding may
allow egress of the lipid from the spatially adjacent binding site.
However, this hypothesis should be experimentally verified.
Conformation of PDI Bound to Large Protein Substrates. Despite
extensive research, so far the mechanistic detail of how PDI in-
teracts with large protein substrates during catalysis of native disul-
fide bond formation has not been elucidated. It has been shown that
PDI requires the a or a′ domains in combination with b′ to perform
oxidation and isomerization function (25) and that the b′ domain
provides the primary binding site while other domains also con-
tribute to binding (26). To date, there is only 1 reported structure of
PDI in complex with a “substrate”molecule, and that was using PDI
from the soft rot fungus Humicola insolens (54). No specificity for
substrate binding by any of the substrate binding sites in PDI has
previously been reported, but the specificity of the substrate binding
site in the b′ domain of PDIp (pancreas-specific PDI) has been
reported to be a single aromatic amino acid with no adjacent neg-
ative charge in the substrate (55). This is consistent with the location
of the side chain of Tyr605 of MTPα in a hydrophobic pocket in
PDI. It is also consistent with the reported inhibition of PDI by
small aromatic molecules, such as bisphenol (56). Determination
of the MTP crystal structure not only gives information of the
potential role of PDI in the complex but also, provides essential
insight into PDI interactions with large proteins, i.e., MTPα may
be considered to be a substrate mimic.
The structure of PDI in the MTP complex is significantly different
from that previously obtained for human full-length PDI alone (39).
While the 4 thioredoxin domains exhibit the same structures (rmsd
0.42 to 0.78 Å for the individual domains compared with reduced
PDI; 4EKZ), the orientation of these domains with respect to each
other changes, with movement of the a′ domain being the most
pronounced change (Fig. 6). Comparison of the 2 catalytic motifs in
PDI from MTP complex with reduced PDI (4EKZ) showed that
binding to MTPα does not distort their geometry.
Conformational exchange in PDI has been reported before and
has been linked both to the substrate bind–release cycle (57) and to
conformational exchange linked to changes in the thiol-disulfide
status of the active sites (58). The 2 previously available crystal
structures of human PDI have been reported to represent the oxi-
dized (4EL1) and reduced (4EKZ) states of the protein, with the
major change being the orientation of the domains with respect to
each other (39). This conformational change linked to changes in
redox structure has been potentially linked to function (59), more
specifically to modulating substrate binding. However, it should be
noted that PDI acts to catalyze both the introduction of disulfide
Table 1. Conservation of amino acids in MTPα
Source
β-Barrel
domain, %
α-Helical
domain, %
Lipid-binding
domain, %
All species (300) 3.6 4.6 8.6
Vertebrate (216) 8.9 8.2 18.2
Mammalian + bird (156) 22.5 28.4 38.4
Mammalian (94) 34.6 45.1 52.2
For the vertebrate, mammalian + bird, and mammal datasets, conserva-
tion is set at 100%; for the larger dataset, which may contain a higher pro-
portion of DNA sequencing errors, it is set at 98%.
Fig. 6. Insights on PDI bound to protein substrates. Comparison of PDI conformations in MTP complex (A), oxidized PDI homodimer complex (B; 4EL1), and
the PDI family member ERp57 in complex with Tapasin (C; 3F8U). All 3 molecules were superimposed and are shown in a similar orientation. Active site
cysteines are colored in red and shown in ball and stick representation.
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bonds in folding protein substrate from its oxidized state and the
isomerization of disulfide bonds from its reduced state, and hence,
both states must bind to nonnative protein substrates (60). In silico
analysis suggests that interconversion between the 2 states is possible
through domain motion independent of redox state (61). In the
MTP complex structure, both active sites of PDI are in the reduced
state, but the PDI is not in the “closed” conformation previously
associated with this state; rather, it is in an “open” conformation
with MTPα in the central cavity (Fig. 6). The interaction sites be-
tween PDI and MTPα are juxtaposed to the active sites in the a and
a′ domain and involve the previously identified “primary substrate
binding site” in the b′ domain (26). As such, the bound MTPα most
probably mimics a large substrate protein bound to PDI. The more
open conformation of PDI in the complex reflects the conforma-
tional flexibility of PDI for binding substrates of different sizes.
Several crystal structures of PDI family members have dimers of
PDI in the asymmetric unit or form dimers with symmetry molecule.
These include the first published structure of a PDI, yeast Pdi1p (40)
(2B5E), and the structure of oxidized human PDI (39) (4EL1). In
both of these structures, 1 domain of the other molecule of PDI sits
in the cleft formed between the a, b′, and a′ domains—just as
MTPα sits in the cleft in our complex crystal structure. For oxidized
human PDI, the interaction sites on the a and a′ domains of the
binding molecule mirror those used by PDI to bind MTPα (Fig. 6
and SI Appendix, Fig. S7). In the 4EL1 homodimer structure, the
bound PDI does not formally contact the b′ domain of the binding
molecule. However, 20 amino acids at the N terminus of the protein
along with regions G250 to K254 and L320 to E323, which are in-
volved in MTPα interaction, are missing from the structure, and the
pocket between the bound and binding molecule is sufficiently large
to accommodate all of the missing regions. This conservation of
binding sites along with the requirement for PDI to bind substrate
proteins of different sizes in both its oxidized and reduced states (60,
62–64) suggests that, in the 4EL1 structure, 1 molecule of PDI is
bound as a substrate would be by the other PDI molecule. Hence,
the different structures previously available for human PDI probably
represent the substrate bound and free states rather than repre-
senting differences in redox state per se. A similar pattern of self-
association can be observed in the Pdi1p structure (40).
No structures exist for human PDI binding to other peptide or
protein substrates, but the peptide binding site in human PDI b′
domain has been mapped by NMR (65, 66), and 1 crystal structure
exists for H. insolens PDI b′ to a′ binding to an 11-amino acid
peptide derived from the cytoplasmic protein α-synuclein. The in-
teraction site localized to the b′ domain in both types of study is at an
equivalent site to that seen for MTPα interaction in our complex (SI
Appendix, Fig. S8).
Finally, a heterodimeric complex between the PDI family
member ERp57 and Tapasin has been published (67) (3F8U).
As per MTP, the Tapasin sits in a cleft formed between the a and
a′ domains of ERp57, but in this case, Tapasin is insufficiently
large to make contact with the b′ domain. The interaction sur-
faces of the a and a′ domains of ERp57 with Tapasin are es-
sentially identical with those between PDI a and a′ domains with
MTP (Fig. 6 and SI Appendix, Fig. S9), with the exception of a
mixed disulfide state between ERp57 and Tapasin.
Overall, the data suggest that MTPα is bound by PDI by the
same sites that PDI interacts with substrate proteins during ox-
idative folding and hence, that MTPα can be considered a sub-
strate mimic to study binding interactions.
Materials and Methods
Cloning. The gene encoding human MTP includes residues 19 to 894 (lacking
the N-terminal signal peptide) and was amplified from a human liver com-
plementary DNA library (Clontech). The gene was inserted into a modified
pET23-based vector using NdeI/XhoI restriction site incorporating an
N-terminal hexahistidine tag. The preparation of a polycistronic expression
construct for codon-optimized Erv1p and codon-optimized mature human
PDI (residues 18 to 509) in modified pLysS was described previously (68).
Mutations in MTP were made using the QuikChange mutagenesis kit (Agilent)
according to the manufacturer’s instructions. All plasmids were sequenced to
confirm the correct insertion of genes.
Protein Expression and Purification for Crystallization. Escherichia coli K-12
expression strain cotransformed with DNA plasmids containing MTP
and Erv1-PDI was stored at −70 °C as a stock in 20% glycerol, streaked onto
Luria broth (LB) agar plate supplemented with 100 μg/mL ampicillin and
35 μg/mL chloramphenicol, and incubated at 37 °C. This was used to inoculate
50 mL LB medium supplemented with the corresponding antibiotics, and the
flask was incubated at 37 °C at 200 rpm for 6 h. This culture was used to seed
200 mL autoinduction medium supplemented with corresponding antibiotics
in 2-L Erlenmeyer flasks (5.2 L in total) covered with an oxygen-permeable
membrane to a final optical density at 600 nm of 0.02 and grown overnight
at 30 °C shaking at 250 rpm. In the morning, protein expression was induced
by the addition of Isopropyl β-D-1-thiogalactopyranoside to a final concen-
tration of 0.25 mM, and the expression was continued for the next 24 to 26 h
at 30 °C at 250 rpm. At the end of expression, cells were harvested at
3,220 × g for 20 min, and pellets were stored frozen at −20 °C. Cell
pellets were resuspended in 200 mL of the lysis buffer (50 mM NaP, pH
7.4, 150 mM NaCl, 5 mM Imidazole) supplemented with 0.1 mg/mL lyzo-
zyme. Cells were lysed by 2 cycles of freeze–thaw, and chromosomal DNA
was broken by sonication. Cell debris was cleared out by centrifugation at
25,155 × g for 40 min, and supernatants were filtered through 0.45-μm sy-
ringe filters. Supernatants were loaded into 5-mL HiTrap Chelating column (GE
Healthcare), which was previously equilibrated with the lysis buffer. The flow
through was collected, and column was additionally washed with 50 mL of
50 mMNaP, pH 7.4, 300 mMNaCl, and 10 mM Imidazole. The proteins of interest
were eluted with the step gradient of imidazole, including 20, 40, 50, and
200 mM Imidazole. All fractions were analyzed by sodium dodecyl sulfate/
polyacrylamide gel electrophoresis (SDS/PAGE). Fractions containing the MTP
protein complex were pooled together and concentrated to a final volume of
1.5 mL using a Millipore Amicon Stirred cell with 10-kDa cutoff membrane.
Size exclusion chromatography was performed using a HiLoad Superdex S200
16/60 pg column (GE Healthcare) previously equilibrated with 50 mM BisTris
Propane, pH 7.5, and 200 mMNaCl. Eluted fractions were analyzed on SDS/PAGE,
and fractions containing MTP were combined and concentrated to 4 to 8 mg/mL,
flash frozen in liquid nitrogen, and stored at −70 °C.
Table 2. Data collection and refinement statistics
Crystal data MTP–PDI (PDB ID code 6I7S)
Data collection
Space group P1
Cell dimensions
a, b, c (Å) 77.56, 105.6, 112.2
α, β, γ (°) 89.8, 76.9, 74.2
Resolution (Å) 49.35–2.5 (2.56–2.5)
Rmerge 0.06 (1.39)
Mean I/σI 8.3 (0.5)
Completeness (%) 93.8 (88)
Redundancy 1.7 (1.7)
CC1/2 (%)* 99.8 (21)
Wilson B factor (Å2) 74.6
Refinement
Resolution (Å) 49.35–2.5
No. reflections 108,274
Rwork/Rfree 20.4/25.7
No. atoms 21,452
Protein 20,888
Ligand/ion 342
Water 222
B factors
Protein 72.4
Ligand/ion 86.7
Water 55.6
Rmsds
Bond lengths (Å) 0.006
Bond angles (°) 1.356
Values in parentheses are for highest-resolution shell.
*Described in ref. 85.
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Small-scale production of wild-type MTP and mutants is detailed in
SI Appendix.
Crystallization. Initial crystallization screening was performed in a 96-well
format by the sitting-drop vapor diffusion method using TTP Labtech’s Mos-
quito LCP nanodispenser and commercially available sparse-matrix crystal
screens, JCSG-plus, Morpheus, and MIDAS (Molecular Dimensions) at 22 and
4 °C. After 2 wk, initial plate crystals of ∼5 × 20 × 50 μmwere obtained in 0.1 M
Tris, pH 8.5, 0.2 M Li2SO4, and 40% (vol/vol) PEG400 at 4 °C in a drop containing
0.1 μL of protein and 0.1 μL of crystallization solution. Optimization grid screen
with varying concentration of PEG400 and pH was designed based on the initial
condition but resulted in the same small crystals with no diffraction. Then, initial
crystals were crushed and used for seeding into optimization grid screen with
ratio of 0.1 μL of protein, 0.02 μL seeds, and 0.08 μL of crystallization solution.
This procedure was repeated several times until crystals of satisfactory size and
shape were obtained; however, the best crystals resulted in diffraction only up
to 3.2 to 3.5 Å. Crystals were reproduced, crushed, and used as seeds in the
additive screen prepared using 45 μL of modified initial crystallization condition
(0.1 M Tris, pH 8.0, 0.2 M Li2SO4, 32% [vol/vol] PEG400) mixed with 5 μL of
Additive Screen HT (Hampton Research). Crystallization experiment was set up
as described before (0.1 μL of protein, 0.02 μL seeds, and 0.08 μL of crystalliza-
tion solution) and incubated at 4 °C. Five days later, crystals appeared in crys-
tallization conditions supplemented with 5% Jeffamine M-600, pH 7.0, or 4%
Polypropylene glycol P400. The crystallization seeding experiment was prepared
using 2 to 8% Jeffamine M-600, pH 7.0, or 2 to 8% Polypropylene glycol
P425 mixed with 0.1 M Tris, pH 8.0 to 8.25, 0.2 M Li2SO4, and 30 to 36% (vol/vol)
PEG400. Two weeks later, plate crystals of ∼10 × 100 × 100 μm appeared in
0.1 M Tris, pH 8.25, 0.2 M Li2SO4, 32% (vol/vol) PEG400, and 2% Polypropylene
glycol P425 and were immediately flash frozen in liquid nitrogen.
Data Collection. High-resolution X-ray diffraction data were collected using
MASSIF-1 (69), an automated high-throughput facility on the European
Synchrotron Radiation Facility beamline ID30a-1, at a wavelength of 0.966 Å
and equipped with PILATUS3_2M detector (DECTRIS); 167° of data were
collected using 0.05° oscillation angle and 0.122-s exposure time. X-ray dif-
fraction data were processed using XDS (70).
Structure Determination. CCP4 software suite (71) was used for phasing and
refinement. The structure of the PDI–MTPα complex was solved by a molecular
replacement (MR) method using the structures of separate domains a, b, b′,
and a′ of human PDI from the Protein Data Bank (PDB) ID code 4EKZ (39) and a
large β-sheet domain of lamprey lipovitellin (PDB ID code 1LSH [37]), which has
21% identity to MTPα over 65%of the length. All MRmodels weremodified by
SCULPTOR (72) to eliminate flexible and poorly conserved loops. Original at-
tempts to position the PDI domains using MOLREP (73) were unsuccessful, and
the highest rotation function peaks (higher than 6σ) were observed for the a′
domain. Subsequent search in Phaser (74) starting with the a′ domain allowed
positioning of 2 copies of the a′ domain, 2 copies of the b′ domain, and a single
copy of the a domain with log-likelihood gradient (LLG) = 621. A MOLREP
search with option NP (number of peaks) = 200, where 200 rotation function
peaks were used in the translation search with Phaser solution, used as a fixed
model allowed positioning of a single copy of the b domain. Two full a, b, b′,
and a′ chains of PDI were constructed by a superposition of the partial models
using the b′ domain as a reference and subjected to rigid body refinement in
Phaser (final LLG = 707) as implemented in CCP4i2 (75). REFMAC5 (76) jelly body
refinement of 2 PDI monomers produced a model with R/Rfree of 48.6/50.7.
The SCULPTOR-produced model of MTPα based on lipovitellin structure
was broken into a single helical and 2 β-sheet domains. Two copies of the
large β-sheet domain were positioned by the phased translation function
option in Phaser (LLG = 1,020) with 2 PDI monomers used as a fixed model. This
model refined to R/Rfree values of 44/49. The refined model was subjected to
20 cycles of SHELXE phase extension procedure (77). Although the procedure
did not converge, a number of long helices were built by it, which were added
to the starting model. These belonged to a single α-helical MTPα domain,
and MR search positioned the second copy of this domain. The 2-fold NCS
(noncrystallographic symmetry) averaging implemented in DM (78) was used
for phase improvement of PDI–MTPα structure, with masks and NCS operators
calculated separately for each domain. Density modification phases were input
for phase refinement in REFMAC5 (79). Resulting electron density maps
allowed us to build the small β-sheet in both MTPα monomers in Coot (80) and
to build amino acid side chains. Multicrystal averaging by DMMULTI (78) was
implemented to include data collected on several nonisomorphous crystals of
PDI–MTPα complex to resolution of better than 3 Å and data for several PDI
structures available in the PDB. BUSTER (81) refinement was used at later
stages of refinement. Model quality was assessed using MolProbity (82). For
Ramachandran analysis, Ramachandran favored 95.83%, Ramachandran
allowed 3.34%, and Ramachandran outliers were 0.83%. Figures were prepared
in UCSF Chimera (83) and PyMol (84). Data collection and refinement statistics
are presented in Table 2.
Biophysical Characterization. Protein concentration was determined by
measurement of absorbance at 280 nm using molar extinction coefficients
based on amino acid composition.
MTP activity was determined using the MTP activity assay kit (Roar Bio-
chemical) according to the manufacturer’s instructions except that the assay
was scaled up to a 0.5- or 1-mL volume and fluorescence was monitored
using a Fluoromax-4 spectrofluorometer (Horiba Scientific). The activity was
measured for 15 min (semipure MTP) or 25 min (purified MTP), over which
time a linear change in signal was observed. The activity assay uses an un-
defined fluorescently labeled lipid, making detailed interpretation of the
effects of individual point mutations problematic.
Far-ultraviolet circular dichroism (CD) spectra were recorded on a
Chirascan-Plus CD spectrophotometer. All scans were collected at 22 °C as an
average of 3 scans using a cell with a path length of 0.05 or 0.1 cm, scan
speed of 1 nm/s, step size of 1 nm, and a spectral bandwidth of 1 nm. The HT
voltage did not exceed 750 V.
Thermofluor assay was performed using a 7500 Real Time PCR System
(Applied Biosystems). For the assay, 22.5 μL of 0.5 mg/mL MTP in 50 mM
phosphate buffer, pH 7.3, was mixed with 2.5 μL of 50× SYPRO Orange
Protein Gel Stain (Sigma Aldrich) dye (original stock 5,000×, diluted to 50× be-
fore the use in 20 mM phosphate buffer, pH 7.5) and loaded onto a 96-well
plate (Micro Amp reaction plate; Applied Biosystems) in 3 to 6 replicates, and the
plate was sealed with a transparent film. The samples were heated from 20 °C to
90 °C, and the fluorescence signal was measured. The melting temperature (Tm)
was determined by examining the derivative of the fluorescence with time.
Data Availability. Coordinates have been deposited in the PDB under ID
code 6I7S.
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